Glutamyl Aminopeptidase Pipeline and Therapeutics Development H1 2017 a provides comprehensive information on the therapeutics under development for Glutamyl Aminopeptidase
Glutamyl Aminopeptidase Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Glutamyl Aminopeptidase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Glutamyl Aminopeptidase pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 18.104.22.168) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.
The latest report Glutamyl Aminopeptidase - Pipeline Review, H2 2017, outlays comprehensive information on the Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 22.214.171.124) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 126.96.36.199) - Glutamyl aminopeptidase is an enzyme encoded by the ENPEP gene. It is a zinc-dependent membrane-bound aminopeptidase that catalyzes the cleavage of glutamatic and aspartatic amino acid residues from the N-terminus of polypeptides.
The enzyme degrades vasoconstricting angiotensin II into angiotensin III and helps to regulate blood pressure. The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively.
Report covers products from therapy areas Cardiovascular, Oncology and Women's Health which include indications Hypertension, Congestive Heart Failure (Heart Failure), Endometriosis, Hepatic (Liver) Tumor, Idiopathic (Essential) Hypertension, Left Ventricular Dysfunction, Neuroblastoma and Resistant Hypertension.
Furthermore, this report also reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 188.8.131.52) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Sample copy is available at www.marketinsightsreports.com/repo…w-h2-2017/inquiry
The Glutamyl Aminopeptidase pipeline guide also reviews of key players involved in therapeutic development for Glutamyl Aminopeptidase and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively.
Browse full Report at www.marketinsightsreports.com/repo…ne-review-h2-2017
Scope of this report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Glutamyl Aminopeptidase. The pipeline guide reviews pipeline therapeutics for Glutamyl Aminopeptidase by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glutamyl Aminopeptidase therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Glutamyl Aminopeptidase therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Glutamyl Aminopeptidase.
- This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glutamyl Aminopeptidase. Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glutamyl Aminopeptidase pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Category: Market Research Publishers and RetailersCompany about: MarketInsightsReports is your single point market research source for all industries including pharmaceutical, chemicals and materials, energy resource, automobile, IT, technology and media, food and beverages, and consumer goods, among others.